 Edward Gardner
Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 48 | 2025 | 2836 | 3.640 |
Why?
| | Anti-HIV Agents | 23 | 2024 | 778 | 2.140 |
Why?
| | HIV Protease Inhibitors | 5 | 2019 | 69 | 1.550 |
Why?
| | HIV-1 | 13 | 2024 | 864 | 1.520 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 233 | 1.490 |
Why?
| | Viral Load | 11 | 2024 | 466 | 1.170 |
Why?
| | Medication Adherence | 9 | 2019 | 467 | 1.140 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2017 | 271 | 1.010 |
Why?
| | HIV Integrase Inhibitors | 3 | 2024 | 70 | 0.950 |
Why?
| | Continuity of Patient Care | 3 | 2021 | 284 | 0.910 |
Why?
| | Tenofovir | 10 | 2024 | 243 | 0.900 |
Why?
| | Adenine | 10 | 2024 | 271 | 0.860 |
Why?
| | Patient Compliance | 5 | 2017 | 581 | 0.780 |
Why?
| | Drug Resistance, Viral | 5 | 2011 | 116 | 0.770 |
Why?
| | Darunavir | 1 | 2019 | 19 | 0.610 |
Why?
| | Organophosphates | 6 | 2020 | 134 | 0.600 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 32 | 0.600 |
Why?
| | Mass Screening | 7 | 2025 | 1287 | 0.580 |
Why?
| | Emtricitabine | 8 | 2019 | 175 | 0.570 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2069 | 0.540 |
Why?
| | Hepatitis C | 4 | 2025 | 271 | 0.530 |
Why?
| | Antiviral Agents | 5 | 2021 | 744 | 0.520 |
Why?
| | Healthcare Disparities | 1 | 2021 | 654 | 0.450 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 230 | 0.430 |
Why?
| | Adult | 48 | 2025 | 37929 | 0.430 |
Why?
| | Health Services Administration | 1 | 2013 | 8 | 0.430 |
Why?
| | Alanine | 3 | 2024 | 152 | 0.420 |
Why?
| | Middle Aged | 41 | 2025 | 33479 | 0.410 |
Why?
| | Hepacivirus | 4 | 2025 | 261 | 0.400 |
Why?
| | Male | 53 | 2025 | 67762 | 0.400 |
Why?
| | Public Health Administration | 1 | 2013 | 76 | 0.390 |
Why?
| | HIV | 4 | 2021 | 234 | 0.390 |
Why?
| | Humans | 69 | 2025 | 137585 | 0.380 |
Why?
| | Female | 52 | 2025 | 73304 | 0.370 |
Why?
| | Pneumococcal Infections | 2 | 2024 | 115 | 0.370 |
Why?
| | Pyrrolidinones | 1 | 2011 | 28 | 0.370 |
Why?
| | CD4 Lymphocyte Count | 7 | 2019 | 269 | 0.360 |
Why?
| | Drug Therapy, Combination | 7 | 2021 | 1066 | 0.360 |
Why?
| | Streptococcus pneumoniae | 2 | 2024 | 169 | 0.360 |
Why?
| | Antibodies, Neutralizing | 3 | 2025 | 286 | 0.350 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 84 | 0.340 |
Why?
| | Fees and Charges | 1 | 2010 | 10 | 0.330 |
Why?
| | Current Procedural Terminology | 1 | 2010 | 19 | 0.330 |
Why?
| | Pyridones | 2 | 2024 | 168 | 0.330 |
Why?
| | Patient Education as Topic | 3 | 2016 | 766 | 0.330 |
Why?
| | Dried Blood Spot Testing | 4 | 2019 | 104 | 0.330 |
Why?
| | Online Systems | 1 | 2009 | 21 | 0.320 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2010 | 82 | 0.320 |
Why?
| | Fibromyalgia | 1 | 2009 | 52 | 0.310 |
Why?
| | Drug Overdose | 3 | 2019 | 347 | 0.300 |
Why?
| | Rheumatology | 1 | 2010 | 118 | 0.300 |
Why?
| | Delivery of Health Care | 3 | 2014 | 951 | 0.300 |
Why?
| | Organophosphonates | 3 | 2015 | 93 | 0.290 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.290 |
Why?
| | Deoxycytidine | 3 | 2015 | 179 | 0.280 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 591 | 0.270 |
Why?
| | Naloxone | 3 | 2018 | 122 | 0.270 |
Why?
| | Clostridium Infections | 1 | 2008 | 73 | 0.260 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2009 | 242 | 0.260 |
Why?
| | Treatment Outcome | 11 | 2025 | 10811 | 0.250 |
Why?
| | Narcotic Antagonists | 3 | 2018 | 181 | 0.250 |
Why?
| | Prospective Studies | 13 | 2025 | 7604 | 0.250 |
Why?
| | Analgesics, Opioid | 4 | 2019 | 1000 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 804 | 0.240 |
Why?
| | Kartagener Syndrome | 1 | 2005 | 30 | 0.240 |
Why?
| | Health Care Costs | 2 | 2011 | 398 | 0.240 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 68 | 0.240 |
Why?
| | Immunization, Passive | 1 | 2025 | 90 | 0.230 |
Why?
| | Macrolides | 1 | 2005 | 65 | 0.230 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2005 | 78 | 0.230 |
Why?
| | Blood Chemical Analysis | 3 | 2014 | 99 | 0.230 |
Why?
| | Lymphocyte Activation | 3 | 2021 | 1142 | 0.230 |
Why?
| | Anus Neoplasms | 1 | 2025 | 33 | 0.230 |
Why?
| | Lymphopenia | 1 | 2025 | 62 | 0.230 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2005 | 62 | 0.230 |
Why?
| | Patient Acceptance of Health Care | 1 | 2011 | 806 | 0.220 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 66 | 0.220 |
Why?
| | Nasopharynx | 1 | 2024 | 76 | 0.220 |
Why?
| | Pre-Exposure Prophylaxis | 3 | 2017 | 213 | 0.220 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 390 | 0.210 |
Why?
| | Desiccation | 2 | 2014 | 19 | 0.210 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 17 | 0.210 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 189 | 0.210 |
Why?
| | Cohort Studies | 6 | 2025 | 5742 | 0.200 |
Why?
| | Retrospective Studies | 11 | 2024 | 15657 | 0.200 |
Why?
| | RNA, Viral | 4 | 2025 | 656 | 0.200 |
Why?
| | Specimen Handling | 2 | 2014 | 183 | 0.190 |
Why?
| | Quality of Life | 3 | 2025 | 2892 | 0.190 |
Why?
| | Sepsis | 1 | 2008 | 617 | 0.180 |
Why?
| | Vaccines, Conjugate | 1 | 2021 | 65 | 0.180 |
Why?
| | Viremia | 2 | 2019 | 138 | 0.170 |
Why?
| | Weight Gain | 1 | 2024 | 519 | 0.170 |
Why?
| | Substance-Related Disorders | 2 | 2018 | 1083 | 0.170 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1167 | 0.170 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2021 | 127 | 0.170 |
Why?
| | Research Subjects | 1 | 2020 | 42 | 0.170 |
Why?
| | Adaptive Immunity | 1 | 2021 | 165 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 142 | 0.160 |
Why?
| | Internship and Residency | 1 | 2010 | 1147 | 0.160 |
Why?
| | Gender Identity | 1 | 2020 | 124 | 0.160 |
Why?
| | Time-to-Treatment | 1 | 2021 | 205 | 0.160 |
Why?
| | Sustained Virologic Response | 1 | 2019 | 40 | 0.160 |
Why?
| | Sexual and Gender Minorities | 2 | 2020 | 214 | 0.160 |
Why?
| | Oxazines | 1 | 2019 | 30 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 3 | 2016 | 558 | 0.150 |
Why?
| | Colorado | 5 | 2018 | 4565 | 0.140 |
Why?
| | Rectum | 2 | 2016 | 185 | 0.140 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 16 | 0.140 |
Why?
| | Atazanavir Sulfate | 2 | 2015 | 41 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2019 | 216 | 0.140 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 786 | 0.130 |
Why?
| | Homosexuality, Male | 2 | 2016 | 184 | 0.130 |
Why?
| | B-Lymphocytes | 2 | 2021 | 847 | 0.130 |
Why?
| | Microbiota | 1 | 2024 | 762 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 30 | 0.130 |
Why?
| | Piperazines | 1 | 2019 | 350 | 0.130 |
Why?
| | Chronic Pain | 2 | 2018 | 262 | 0.120 |
Why?
| | Secondary Prevention | 1 | 2017 | 233 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2015 | 38 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 137 | 0.110 |
Why?
| | Time Factors | 4 | 2016 | 6828 | 0.110 |
Why?
| | Mental Health Services | 1 | 2019 | 421 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 852 | 0.110 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 62 | 0.110 |
Why?
| | Young Adult | 10 | 2024 | 13209 | 0.110 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 19 | 0.100 |
Why?
| | Biomarkers | 6 | 2021 | 4149 | 0.100 |
Why?
| | Aged | 9 | 2025 | 23961 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 236 | 0.100 |
Why?
| | Risk Factors | 5 | 2025 | 10388 | 0.100 |
Why?
| | Vaccination | 1 | 2021 | 1381 | 0.100 |
Why?
| | Genotype | 2 | 2025 | 1916 | 0.090 |
Why?
| | Zidovudine | 1 | 2012 | 78 | 0.090 |
Why?
| | Lamivudine | 1 | 2012 | 63 | 0.090 |
Why?
| | United States | 4 | 2024 | 14841 | 0.090 |
Why?
| | Intention to Treat Analysis | 2 | 2021 | 73 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1477 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1077 | 0.090 |
Why?
| | Population Surveillance | 1 | 2014 | 482 | 0.090 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2010 | 14 | 0.090 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.080 |
Why?
| | Treatment Failure | 2 | 2021 | 356 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1996 | 0.080 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 433 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1289 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2021 | 3556 | 0.080 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 108 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2009 | 88 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 532 | 0.070 |
Why?
| | Adolescent | 8 | 2021 | 21513 | 0.070 |
Why?
| | Hospitalization | 3 | 2025 | 2199 | 0.070 |
Why?
| | Public Health | 1 | 2013 | 588 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1329 | 0.070 |
Why?
| | Comprehension | 1 | 2009 | 172 | 0.070 |
Why?
| | Oligopeptides | 1 | 2009 | 271 | 0.070 |
Why?
| | Cost Savings | 1 | 2008 | 84 | 0.070 |
Why?
| | Educational Status | 1 | 2009 | 470 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 106 | 0.070 |
Why?
| | Disease Progression | 2 | 2023 | 2757 | 0.060 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 115 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2021 | 1993 | 0.060 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1809 | 0.060 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 112 | 0.060 |
Why?
| | Osteomyelitis | 1 | 2008 | 132 | 0.060 |
Why?
| | Pyridines | 1 | 2009 | 506 | 0.060 |
Why?
| | Axonemal Dyneins | 1 | 2005 | 9 | 0.060 |
Why?
| | Dyneins | 1 | 2005 | 33 | 0.060 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2005 | 27 | 0.060 |
Why?
| | Inflammation | 1 | 2016 | 2837 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 88 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1316 | 0.060 |
Why?
| | Mycobacterium avium Complex | 1 | 2005 | 88 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2025 | 148 | 0.060 |
Why?
| | Half-Life | 2 | 2016 | 164 | 0.060 |
Why?
| | Nasal Mucosa | 1 | 2005 | 107 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 297 | 0.060 |
Why?
| | Oropharynx | 1 | 2024 | 46 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 143 | 0.060 |
Why?
| | Electronic Health Records | 2 | 2025 | 1069 | 0.060 |
Why?
| | Gene Expression | 1 | 2009 | 1502 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 35 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 54 | 0.050 |
Why?
| | Pilot Projects | 1 | 2009 | 1710 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 786 | 0.050 |
Why?
| | Bronchiectasis | 1 | 2005 | 111 | 0.050 |
Why?
| | Spleen | 1 | 2005 | 514 | 0.050 |
Why?
| | Curriculum | 1 | 2010 | 992 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2008 | 400 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1946 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1509 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3457 | 0.050 |
Why?
| | Logistic Models | 1 | 2008 | 2074 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 549 | 0.050 |
Why?
| | Recurrence | 1 | 2005 | 1060 | 0.050 |
Why?
| | Medical Futility | 1 | 2021 | 23 | 0.050 |
Why?
| | Primary Health Care | 3 | 2018 | 1738 | 0.050 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 10 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 30 | 0.040 |
Why?
| | Ultrasonography | 1 | 2005 | 759 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2025 | 625 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 329 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2828 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2021 | 146 | 0.040 |
Why?
| | Transsexualism | 1 | 2020 | 20 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3958 | 0.040 |
Why?
| | Plasma | 2 | 2012 | 212 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 139 | 0.040 |
Why?
| | Qualitative Research | 2 | 2016 | 1386 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2019 | 82 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1070 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2006 | 986 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5131 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 135 | 0.040 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1171 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 318 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 10 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2844 | 0.030 |
Why?
| | Cell Communication | 1 | 2018 | 315 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1943 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 594 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 94 | 0.030 |
Why?
| | Ribavirin | 1 | 2016 | 91 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 564 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 792 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2691 | 0.030 |
Why?
| | Blood | 1 | 2015 | 107 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 778 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1622 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5472 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2016 | 164 | 0.030 |
Why?
| | Risk | 1 | 2016 | 912 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2031 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2015 | 245 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 669 | 0.030 |
Why?
| | Mental Health | 1 | 2019 | 726 | 0.030 |
Why?
| | Focus Groups | 1 | 2015 | 522 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 417 | 0.020 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 236 | 0.020 |
Why?
| | Dideoxynucleotides | 1 | 2012 | 14 | 0.020 |
Why?
| | Cytidine Triphosphate | 1 | 2012 | 16 | 0.020 |
Why?
| | Thymine Nucleotides | 1 | 2012 | 16 | 0.020 |
Why?
| | Self Report | 1 | 2016 | 827 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 9 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 92 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1096 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 116 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2010 | 247 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2010 | 303 | 0.020 |
Why?
| | Prednisone | 1 | 2010 | 240 | 0.020 |
Why?
| | Drug Interactions | 1 | 2010 | 410 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.020 |
Why?
| | Ritonavir | 1 | 2009 | 74 | 0.020 |
Why?
| | Doxorubicin | 1 | 2010 | 362 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 1118 | 0.020 |
Why?
| | Haplotypes | 1 | 2009 | 494 | 0.020 |
Why?
| | Erythrocytes | 1 | 2012 | 700 | 0.020 |
Why?
| | Animals | 1 | 2009 | 36940 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 812 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 660 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 2071 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7635 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2900 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5778 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1692 | 0.010 |
Why?
|
|
Gardner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|